Treatment of the haematological relapse in patients suffering from acute myeloid leukaemia or myelodysplastic syndrome with 5-Azacytidin (Vidaza®) after hematopoietic stem cell transplantation RELAZA - RELAZA

niversity of Technology Dresden0 个研究点开始时间: 2006年7月14日最近更新: 2013年5月13日

试验速览

暂无简介。

•- Age > 18 years
•- Patients with CD34+ acute myeloid leukaemia or myelodysplastic syndrome after hematopoietic stem cell transplantation
•- Written informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•- Known or current abuse of drugs, medications or alcohol
•- Subjects unlikely to comply with the requirements of the protocol
•- Pregnancy or lactation
•- Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or are using a highly effective method of birth control (defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomized partner
•- Participation in another clinical trial within the last four weeks

发起方

niversity of Technology Dresden